Overview
Taking into consideration prevalent (the COVID-19 pandemic) and anticipated future trends, the global vaccines market is expected to be worth around USD 100 billion by 2025. Recent estimates (as reported in April 2021) suggest that more than 1.06 billion doses have been administered across 172 countries, which roughly translates to 19.7 million doses per day. Although the pandemic is responsible for the current surge in the demand for vaccines, according to the WHO, the current global vaccination rate is nearly 85%. As a result, as the global population grows, the demand for manufacturing vaccines is likely to increase, as well. It is worth highlighting that the vaccine development process is characterized by the need for heavy investments in specialized infrastructure and affiliated expertise, and complex R&D and production protocols. Further, vaccine manufacturing is highly regulated, and due to increasing regulatory stringency, it is gradually becoming difficult for vaccine developers to establish in-house capabilities for the large-scale manufacturing of proprietary vaccine candidates, while ensuing compliance to the evolving standards. As a result, outsourcing vaccine manufacturing operations has become a preferred practice in this segment of the biopharmaceutical industry. The outsourcing-based operating model is common among small and mid-sized innovators, which heavily rely on capable contract manufacturing organizations (CMOs) for clinical- and commercial-scale manufacturing requirements. Over time, several big pharma players, with established in-house capabilities, have also been observed to enter into long-term business relationships with CMOs, in order to optimize internal resource utilization, manage cost of operations, and leverage the niche expertise of specialty service providers.
The contemporary contract services market for vaccines is highly fragmented, featuring a mix of small and mid-sized firms, and established players. Numerous stakeholders presently claim to be actively striving to expand their respective service portfolios; in this context, there has been substantial acquisition activity in this domain, in the recent past. As a result, several of the larger CMOs have developed the required capabilities and expertise to offer end-to-end services, ranging from vaccine development (which includes preliminary R&D, preclinical studies and clinical trials) to regulatory filings, and commercial scale production. It is worth mentioning that to fulfil the growing demand for COVID-19 vaccines and ensure minimal disruption in the supply of these vaccines, several big pharmaceutical companies (such as Bayer, Merck, and Novartis) have offered their manufacturing infrastructure for production of COVID-19 vaccines. Other recent developments in this field include capability expansions, and collaborations focused on expanding geographical presence. In the foreseen future, we expect the demand for core competencies to continue to drive sponsor companies to rely on contract service providers for various aspects of vaccine development and manufacturing. Amidst the tough competition within this domain, the availability of cutting-edge tools and technologies has emerged as a differentiating factor, offering competitive advantage to CMOs that possess them. Given the increased impetus on outsourcing vaccine manufacturing, we anticipate the vaccine contract manufacturing market to grow at a steady pace over the next decade.
Scope Of the Report
The “Vaccine Contract Manufacturing Market (3rd Edition) by Outsourced Business Operations (Cell / Virus Banking, Analytical Testing, Formulation Development, Process Development, Fill / Finish, and Regulatory Filings), Type of Expression Systems (Mammalian, Microbial, and Others), Size of the Company (Small-sized, Mid-sized and Large / Very Large), Scale of Operation (Preclinical / Clinical and Commercial), and Geography (North America (the US), Europe (UK, France, Germany, Italy and Spain), Asia (China, India, Japan and South Korea) and Rest of the World (South Africa): Industry Trends and Global Forecasts” report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs.
Amongst other elements, the report includes:
- A detailed review of the overall landscape of the vaccine contract manufacturing market, featuring a list of active CMOs and an analysis based on a number of relevant parameters, such as year of establishment, size of employee base, location of headquarters, number of vaccine manufacturing facilities, type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others) and type of vaccine manufactured (protein vaccine, viral vaccine, DNA vaccine, cancer vaccine, and others).
- A detailed review of the contract manufacturing landscape for COVID-19 vaccines, featuring a list of service providers and an analysis based on type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) and geographical location of contract manufacturers (North America, Europe, and Asia-Pacific and Rest of the World), along with competitiveness analysis of companies based in different geographies.
- A region-wise company competitiveness analysis, highlighting the most prominent vaccine contract manufacturers, based on supplier strength (in terms of experience), and service strength (in terms of service offerings, expression systems used, and scale of operation).
- Elaborate profiles of the key players based in North America, Europe, and Asia-Pacific having a diverse range of capabilities for development, manufacturing and packaging of vaccines. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, vaccine manufacturing facilities, recent developments and an informed future outlook.
- An analysis of the collaborations that have been established since 2013, based on various parameters, such as year of agreement, type of agreement, scale of operation, type of services mentioned in the deal, type of vaccines manufactured, key therapeutic areas, and location of facility where the project is to be executed.
- A detailed analysis of the expansions undertaken (since 2013) by various vaccine contract manufacturing service providers for enhancing their service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion, capability expansion, facility expansion, and new facility), geographical location of facility, scale of operation, type of service(s) offered, highlighting most active players and other details (in terms of new area added to existing facilities, if available).
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during the time period between 2013-2021, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples (based on revenues), number of employees, and overall experience of the acquired company.
- A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small, mid-sized, large / very large CMOs) in the market, based on data gathered via secondary and primary research. In addition, the study provides the distribution of global vaccine manufacturing capacity by company size (small, mid-sized, large / very large), geography (North America, Europe and Asia-Pacific), and scale of operation (preclinical / clinical and commercial).
- An informed estimate of the annual commercial and clinical demand for vaccines (in million liters), which was further segmented as across different types of vaccines, target indications, and geographies.
- A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
- A discussion on the potential market drivers, such as the growing vaccines pipeline, increasing outsourcing of vaccine operations and opportunities in the Asia-Pacific region, which are likely to present in the coming years.
One of the key objectives of the report was to estimate the existing market size and future growth opportunities. Based on various parameters, such as growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of expression system used (mammalian, microbial, and others), [B] scale of operation (preclinical, clinical, and commercial), [C] company size (small-, mid-sized and large / very large), and [D] key geographical regions (North America (the US), Europe (Italy, Germany, France, Spain, and the UK), and Asia-Pacific (China, India, and Japan), and Rest of the World. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.
The report features detailed transcripts of interviews held with the following industry stakeholders:
- Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
- Dietmar Katinger, Chief Executive Officer, Polymun Scientific
- David C Cunningham, Director Corporate Development, Goodwin Biotechnology
- Ingrid Kromann, Ex-Director – Vaccine Development (currently, the Head of CMC at CEPI)
- Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
- Thilo Kamphausen, Director Business Development, Richter-Helm BioLogics
- Sebastian Schuck, Head of Business Development, Wacker Biotech
- Oliver Schub, Senior Business Development Manager, ProBioGen
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the key players offering vaccine manufacturing services?
- Which manufacturing services are commonly offered by the vaccine contract manufacturers?
- Which partnership models are most commonly adopted by stakeholders engaged in this industry?
- What are the key value drivers of the merger and acquisition activity within this domain?
- What is the current capacity of vaccine contract manufacturing?
- What is the annual commercial and clinical demand for vaccines?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to vaccine contract manufacturing?
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
Companies Mentioned
- 3P Biopharmaceuticals
- ABEC
- Abenza
- Acambis
- Accinov (acquired by ABL)
- Accugenix (acquired by Charles River Laboratories)
- Actavis
- AdaptVac
- Adimmune
- Advanced BioScience Laboratories (ABL)
- Advaxis
- Advent
- Aeras
- Aeras's Biopharmaceutical Development Center (BDC)
- AGC Biologics
- AJ Biologics
- Ajinomoto Bio-Pharma Services
- Akers Biosciences
- Akorn India (acquired by Biological E)
- Akshaya Bio
- Albany Molecular Research
- Alexion Pharmaceuticals
- Algonomics
- Altaris Capital Partners
- Altimmune
- Amatsigroup
- AmbioPharm
- AmpTec (acquired by Merck)
- AnaSpec
- Aptuit
- Arabio
- Aragen Bioscience
- Arcturus Therapeutics
- Argonaut Manufacturing Services
- Aspen Pharmacare
- Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
- AstraZeneca
- Aventis Pasteur
- Avid Bioservices
- Bachem
- Batavia Biosciences
- Battelle
- Bavarian Nordic
- Baxter BioPharma Solutions
- Bayer
- Baylor College of Medicine
- Baylor Institute for Immunology Research (BIIR)
- BD Biosciences
- Bharat Biotech
- Bharat Serums and Vaccine
- Bill & Melinda Gates Foundation
- Bilthoven Biologicals
- Binex
- BioCell
- Biocon
- BioConnections
- Biodextris
- Bio-Ess Laboratories
- Biofabri
- Biofarma
- Biogen
- Bioline (acquired by Meridian Life Sciences)
- Biological E
- BioMARC
- Biomay
- Biomed Research International
- Biomedical Advanced Research and Development Authority (BARDA)
- BioMotiv
- BiondVax Pharmaceuticals
- BioNTech
- BioReliance
- BioTechLogic
- BioTechnique
- Biotechnology and Biological Sciences Research Council
- Biotechnology Development for Industry
- Biovac
- BioVaxys Technology
- Biovest International
- BirgiMefar
- Blue Water Vaccines
- Boehringer Ingelheim BioXcellence
- Boston Children’s Hospital
- Brammer Bio (acquired by Thermo Fisher Scientific)
- BravoVax
- Bristol-Myers Squibb
- Bryllan
- Burrard Pharmaceuticals
- CALIXAR
- Canadian Animal Health Institute (CAHI)
- Cangene
- CARBOGEN AMCIS
- Catalent
- Celsis International (acquired by Charles River Laboratories)
- Centers for Disease Control and Prevention (CDC)
- Century Pharmaceuticals
- CEPiA
- Cetus
- CEVEC
- Changchun BCHT Biotechnology
- Charles River Laboratories
- Chimera Biotec
- China Agricultural University
- China National Biotec Group (CNBG)
- Chinese Center for Disease Control and Prevention
- Chinese University of Hong Kong
- Chiron Behring Vaccines
- Coalition for Epidemic Preparedness Innovations (CEPI)
- Cobra Biologics
- Cognate BioServices
- Commonwealth Serum Laboratories (CSL)
- Cook Pharmica
- CordenPharma
- Crucell
- CureVac
- Cytovance Biologics
- Daiichi Sankyo
- Dalton Pharma Services
- de Duve Institute
- Delpharm
- Deltamune
- Department of Defense
- Dermapharm
- Disposable Lab
- Dr. Reddy's Laboratories
- Dyadic International
- Dynavax Technologies
- EGYVAC
- EirGenix
- Emergent BioSolutions
- Endo International
- Engineering and Physical Sciences Research Council
- Epygen Biotech
- ERC Belgium
- EuBiologics
- Eurogentec
- European Commission
- European Medicines Agency
- ExpreS2ion Biotechnologies
- Exxell BIO
- Fareva
- Federation of Indian Chambers of Commerce and Industry (FICCI)
- Florida Biologix
- FluGen
- Frederick National Laboratory
- French National Agency for Research on AIDS and Viral Hepatitis
- Friedrich-Loeffler-Institut
- FUJIFILM Diosynth Biotechnologies
- Gallant Custom Laboratories
- Gamma Vaccines
- GAVI Alliance
- GC Cell
- GC Pharma
- Genentech
- Geneos Therapeutics
- GENEWIZ
- GenIbet Biopharmaceuticals
- Genopis (acquired by Wacker Biotech)
- Genzyme Polyclonals
- GeoVax
- GlaxoSmithKline
- GNH India
- Goodwin Biotechnology
- Grand River Aseptic Manufacturing
- GreenPak Biotech
- GreenSignal Bio Pharma
- Griffith University
- Grifols
- GSAL
- GTP Technology
- Guangxi Veterinary Research Institute
- Guangzhou Air force Hospital
- Haffkine Institute
- HALIX
- Harbin Veterinary Research Institute (HVRI)
- Health Biotech
- Heat Biologics
- Hennepin Healthcare Research Institute (HHRI)
- Hetero Biopharma
- HLL Biotech
- Hong Kong Institute of Biotechnology
- IDT Biologika
- IMAXIO
- ImevaX
- Immune Design
- Immune Targeting Systems
- Immunex
- ImmunityBio
- Immunobiological Technology Institute (Bio-Manguinhos)
- ImmunoSite Technologies
- ImVisioN Therapeutics
- Index Ventures
- Indian Council of Medical Research
- Indian Immunologicals
- Infectious Disease Research Institute
- Innovate UK
- INOVIO
- INSERM-ANRS
- Instituto Butantan
- Insud Pharma
- Intas
- Integrity Bio
- International AIDS Vaccine Initiative (IAVI)
- International Medica Foundation
- International Society for Pharmaceutical Engineering
- International Vaccine Institute
- Interros
- Intervacc
- Inviragen (acquired by Takeda Pharmaceutical)
- Irvine Pharmaceutical Services
- Israel Institute for Biological Research (IIBR)
- Janssen Pharmaceuticals
- Janssen Vaccines & Prevention
- Jenner Institute
- JHL Biotech
- JHP Pharmaceuticals
- Johnson & Johnson
- JSR
- Jubilant HollisterStier
- KABS Pharmaceutical Services
- Kalon Biotherapeutics (acquired by FUJIFILM Diosynth Biotechnologies)
- Kaneka
- Karolinska Institutet
- KBI Biopharma
- Keensight Capital
- Kemwell Biopharma
- Kitasato Daiichi Sankyo Vaccine
- KP Pharmaceutical Technology
- KU Leuven
- Liaoning Chengda Biological
- LigoCyte Pharmaceuticals (acquired by Takeda Pharmaceutical)
- Lonza
- LuinaBio
- Liminal Biosciences
- Magellan BioScience Group
- Massachusetts General Hospital
- MassBiologics
- Medicago
- Medicines and Healthcare products Regulatory Agency
- Merck
- Meridian Life Science
- MilliporeSigma
- Minhai Biotechnology
- Ministry of Health & Welfare, South Korea
- Minneapolis Medical Research Foundation (MMRF)
- Mitsubishi Gas Chemical
- Mitsubishi Tanabe Pharma
- Moderna Therapeutics
- MSD France
- Mymetics
- Najít Technologies
- Nanotherapeutics
- National Avian Influenza Reference Laboratory
- National Cancer Institute
- National Health Research Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health (NIH)
- NewLink Genetics
- Nitto Avecia Pharma Services
- Norwegian Institute of Public Health
- Nouscom
- Novartis
- Novasep
- Novavax
- OctoPlus
- Ocugen
- Ohio State Innovation Foundation (OSIF)
- Okairos
- Ology Bioservices
- Oncotest
- Oragenics
- Organisation for Economic Co-operation and Development (OECD)
- OSO BioPharmaceuticals Manufacturing (acquired by AMRI)
- Ottawa Hospital Research Institute (OHRI)
- Oxford Biomedica
- Oxford University
- Pacific GMP
- Panacea Biotec
- Panacea Pharmaceuticals
- Paragon Bioservices
- PATH
- Patheon
- PaxVax
- Petrovax
- Pfenex
- Pfizer
- Pfizer CentreOne
- PharmaPak (acquired by Catalent Pharma Solutions)
- PharmaSynth
- Phlow
- Pierre Fabre
- Piramal Pharma Solutions
- Polymun Scientific
- Porton Biopharma
- Praha Vaccines (acquired by Novavax)
- Precisa Medicamentos
- Premas Biotech
- Prime European Therapeuticals (acquired by Livia)
- ProBioGen
- Profectus BioSciences
- Prometic Life Sciences
- Protagen
- PX’Therapeutics
- QuiaPEG Pharmaceuticals
- RAFAGEN
- Recipharm
- Refana
- Reliance Life Sciences
- Rentschler Biopharma
- Richter-Helm BioLogics
- RIEMSER Pharma (acquired by Esteve)
- Rommelag CMO
- ROVI Pharma Industrial Services
- Russian Direct Investment Fund (RDIF)
- SAFC
- Saiba
- Sanofi
- Sanofi Active Ingredient Solutions
- Sanofi Pasteur
- Sanofi-Aventis
- Sartorius Stedim Biotech
- Scancell
- Seikagaku
- Seoul National University Hospital
- Seqirus
- Serum Institute of India
- Shandong Zhaoxin Bio-tech
- Shanghai Laboratory Animal Center
- ShangPharma Innovation
- Shasun Pharmaceuticals
- Shenzhen Kangtai Biological Products
- SialoCarb
- Sichuan Agricultural University
- Siegfried
- Sigma-Aldrich
- Singota Solutions
- SK Bioscience
- SK Chemicals
- Soligenix
- South African Tuberculosis Vaccine Initiative (SATVI)
- South China Agricultural University
- Spicona
- SpyBiotech
- Stabilitech Biopharma
- State Secretariat for Education, Research and Innovation
- Statens Serum Institut
- Stellar Biotechnologies
- Sumagen
- Swissfillon
- Symbiosis Pharmaceutical Services
- SynCo Bio Partners
- Syngene
- Synthelis
- Takara Bio
- Takeda Pharmaceuticals
- Temasek Life Sciences Ventures
- The Cell and Gene Therapy Catapult
- The Coalition for Epidemic Preparedness Innovations (CEPI)
- The Friedrich-Loeffler-Institut
- The Hong Kong Jockey Club Charities Trust
- The Wistar Institute
- Themis Medicare
- TheraVectys
- Thermo Fisher Scientific
- Thomas Jefferson University
- Tianjin CanSino Biotechnology
- Tonix Pharmaceuticals
- Transgene
- Translate Bio
- Unitech Pharmaceuticals
- United Nations International Children's Emergency Fund (UNICEF)
- United States Army Medical Research Institute of Infectious Diseases
- Univercells
- Universitätsklinikum Tübingen
- University of Copenhagen
- University of Iowa Pharmaceuticals
- University of Maryland
- University of Oxford
- University of Pennsylvania
- University of Tokyo
- University of Wisconsin - Madison
- Upperton Pharma Solutions
- Vaccibody
- Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO- InterVac)
- Vaccines Manufacturing and Innovation Centre (VMIC)
- Vaccitech
- VACSERA
- Valerius Biopharma
- Valneva
- Vaxart
- Vaxess Technologies
- Vetter Pharma
- VGXI
- Vibalogics
- VIRCHOW BIOTECH
- Vivalis
- Vipassana Research Institute (VRI)
- Vybion
- Wacker Biotech
- Waisman Biomanufacturing
- Walter Reed Army Institute of Research
- Washington University School of Medicine
- Wellcome Trust
- WIL Research
- Wockhardt
- World Trade Organization
- WuXi AppTec
- WuXi Biologics
- Wuxi Fortune Pharmaceutical
- Wuxi Griffin
- Zoetis
- Zydus Cadila
Methodology
LOADING...